Molecular Mechanism of the β 3 AR Agonist Activity of a β‐Blocker
Abstract Development of subtype‐selective drugs for G protein‐coupled receptors poses a significant challenge due to high similarity between subtypes, as exemplified by the three β‐adrenergic receptors (βARs). The β 3 AR agonists show promise for treating the overactive bladder or preterm birth, but...
Saved in:
Published in | ChemPlusChem (Weinheim, Germany) |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
18.09.2024
|
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract Development of subtype‐selective drugs for G protein‐coupled receptors poses a significant challenge due to high similarity between subtypes, as exemplified by the three β‐adrenergic receptors (βARs). The β 3 AR agonists show promise for treating the overactive bladder or preterm birth, but their potential is hindered by off‐target activation of β 1 AR and β 2 AR. Interestingly, several β‐blockers, which are antagonists of the β 1 ARs and β 2 ARs, have been reported to exhibit agonist activity at the β 3 AR. However, the molecular mechanism remains elusive. Understanding the underlying mechanism should facilitate the development of β 3 AR agonists with improved selectivity and reduced off‐target effects. In this work, we determined the structures of human β 3 AR in complex with the endogenous agonist epinephrine or with a synthetic β 3 AR agonist carazolol, which is also a high‐affinity β‐blocker. Structure comparison, mutagenesis studies and molecular dynamics simulations revealed that the differences on the flexibility of D 3.32 directly contribute to carazolol's distinct activities as an antagonist for the β 2 AR and an agonist for the β 3 AR. The process is also indirectly influenced by the extracellular loops (ECL), especially ECL1. Taken together, these results provide key guidance for development of selective β 3 AR agonists, paving the way for new therapeutic opportunities. |
---|---|
ISSN: | 2192-6506 2192-6506 |
DOI: | 10.1002/cplu.202400288 |